Category Archives: Gesundheit/Medizin

Gesundheit/Medizin

Plastische Chirurgie in Bamberg

Plastische Chirurgie in Bamberg

Praxisklinik Dr. Aletta Eberlein feiert 10-jähriges Bestehen

Diskretion und Wohlfühlambiente verbunden mit hochmoderner Technik

 

Im Mai 2008 eröffnete die Praxisklinik für Plastische Chirurgie Dr. Aletta Eberlein im Herzen Bambergs und erfreut sich seither großer Beliebtheit bei Patienten aus dem gesamten Fränkischen Raum und darüber hinaus. Dr. Eberlein bietet als Fachärztin für Plastische Chirurgie mit ihrer über 25-jährigen Operationserfahrung ein breites Behandlungsspektrum im Bereich der ästhetischen Plastischen Chirurgie, der sogenannten „Schönheitschirurgie“. Die meisten der Eingriffe können in dem diskreten und familiären Umfeld der Praxisklinik ambulant oder kurzstationär durchgeführt werden.

 

Brustoperationen, Fettabsaugungen und Verschönerungen im Gesicht

Welche Verschönerungseingriffe werden bei uns in Franken besonders nachgefragt? „Der überwiegende Schwerpunkt in unserer täglichen Praxis sind Eingriffe an der weiblichen Brust, allen voran die Brustvergrößerungen, aber auch reine Straffungen und Brustverkleinerungen bei überschweren Brüsten. Letztere werden mitunter auch von den Krankenkassen getragen“ berichtet Dr. Eberlein. „Aber auch viele Männer mit etwas Brustansatz lassen diesen korrigieren, ein relativ unkomplizierter Eingriff. Ebenfalls auch von Männern häufig nachgefragt sind Fettabsaugungen im Bauch- und Rückenbereich oder am Hals. Operationen im Gesicht lassen sich erfreulicherweise oft viele Jahre hinauszögern durch nicht-chirurgische Faltenbehandlungen, beispielsweise durch Filler wie Hyaluronsäure oder Botulinumtoxin, besser bekannt als „Botox“. Bei starken Hautüberschüssen ist jedoch meistens das Skalpell sinnvoller, etwa bei ausgeprägten Schlupflidern oder in Situationen, wo ein Facelift angezeigt ist. Welche der mannigfachen Techniken auf dem Markt dann im Einzelfall jeweils zu empfehlen ist, muss man natürlich immer individuell und in einem persönlichen Beratungsgespräch herausfinden.“

 

Was gibt es neues in der Plastischen Chirurgie?

„Seit gut einem Jahr gibt es extra-leichte Brustimplantate aus Silikon, die sogenannten B-Lite-Implantate. Diese Brustimplantate enthalten sehr feine Lufteinschlüsse und bieten aufgrund ihres geringeren Gewichtes Vorteile wenn relativ große Implantate gewünscht werden oder wenn die Patientin sehr viel Sport treibt. Sehr aktuell/neu ist auch die zunehmende Akzeptanz des Lipofillings, d.h. der Brustvergrößerung durch Eigenfett. Dieses Verfahren der Eigenfettverpflanzung ist zwar prinzipiell nicht neu und wird seit über 10 Jahren eingesetzt zum Gesäß-Aufbau oder zur Faltenbehandlung im Gesicht. Bei der Brust jedoch waren seriöse Chirurgen bisher sehr zurückhaltend, da bis vor kurzem noch nicht ausreichend bekannt war, inwieweit durch ein solches Verfahren möglicherweise die Brustkrebsvorsorge beeinträchtigt werden kann oder ob das Eigenfett sogar ein Auslöser für Brustkrebs sein kann. Diesbezüglich scheint die Brustvergrößerung mit Eigenfett nach aktueller Datenlage jedoch unbedenklich zu sein, was sehr erfreulich ist, weil die Brustvergrößerung mit Eigenfett eine sehr schöne und vor allem natürliche Alternative zu Brustimplantaten bietet.“

 

 

Welche Operationen führen Sie am liebsten durch?

Eigentlich führen mein Team und ich alle von uns angebotenen Behandlungen nach wie vor sehr gern durch. Sogar Fettabsaugungen, obwohl diese körperlich sehr anstrengend sein können, denn die Patienten sind danach erfahrungsgemäß sehr zufrieden. Überhaupt freuen wir uns am meisten, wenn wir mit unserer Arbeit dazu beitragen können, dass sich unsere Patienten in ihrem Körper wohlfühlen.“

Weitere Informationen zur Praxisklinik für Plastische Chirurgie Dr. Eberlein in Bamberg finden Sie auf der homepage der Praxisklinik unter www.plastische-chirurgie-eberlein.de.

 

Praxisklinik für Plastische Chirurgie Dr. med. Aletta Eberlein,

Willy-Lessing-Straße 16, 96047 Bamberg

Tel. 0951-20877890

Sprechzeiten nach Vereinbarung

Parkplätze am Haus

Gesundheit/Medizin

Plastische Chirurgie in Bamberg

Plastische Chirurgie in Bamberg

Praxisklinik Dr. Aletta Eberlein feiert 10-jähriges Bestehen

Diskretion und Wohlfühlambiente verbunden mit hochmoderner Technik

 

Im Mai 2008 eröffnete die Praxisklinik für Plastische Chirurgie Dr. Aletta Eberlein im Herzen Bambergs und erfreut sich seither großer Beliebtheit bei Patienten aus dem gesamten Fränkischen Raum und darüber hinaus. Dr. Eberlein bietet als Fachärztin für Plastische Chirurgie mit ihrer über 25-jährigen Operationserfahrung ein breites Behandlungsspektrum im Bereich der ästhetischen Plastischen Chirurgie, der sogenannten „Schönheitschirurgie“. Die meisten der Eingriffe können in dem diskreten und familiären Umfeld der Praxisklinik ambulant oder kurzstationär durchgeführt werden.

 

Brustoperationen, Fettabsaugungen und Verschönerungen im Gesicht

Welche Verschönerungseingriffe werden bei uns in Franken besonders nachgefragt? „Der überwiegende Schwerpunkt in unserer täglichen Praxis sind Eingriffe an der weiblichen Brust, allen voran die Brustvergrößerungen, aber auch reine Straffungen und Brustverkleinerungen bei überschweren Brüsten. Letztere werden mitunter auch von den Krankenkassen getragen“ berichtet Dr. Eberlein. „Aber auch viele Männer mit etwas Brustansatz lassen diesen korrigieren, ein relativ unkomplizierter Eingriff. Ebenfalls auch von Männern häufig nachgefragt sind Fettabsaugungen im Bauch- und Rückenbereich oder am Hals. Operationen im Gesicht lassen sich erfreulicherweise oft viele Jahre hinauszögern durch nicht-chirurgische Faltenbehandlungen, beispielsweise durch Filler wie Hyaluronsäure oder Botulinumtoxin, besser bekannt als „Botox“. Bei starken Hautüberschüssen ist jedoch meistens das Skalpell sinnvoller, etwa bei ausgeprägten Schlupflidern oder in Situationen, wo ein Facelift angezeigt ist. Welche der mannigfachen Techniken auf dem Markt dann im Einzelfall jeweils zu empfehlen ist, muss man natürlich immer individuell und in einem persönlichen Beratungsgespräch herausfinden.“

 

Was gibt es neues in der Plastischen Chirurgie?

„Seit gut einem Jahr gibt es extra-leichte Brustimplantate aus Silikon, die sogenannten B-Lite-Implantate. Diese Brustimplantate enthalten sehr feine Lufteinschlüsse und bieten aufgrund ihres geringeren Gewichtes Vorteile wenn relativ große Implantate gewünscht werden oder wenn die Patientin sehr viel Sport treibt. Sehr aktuell/neu ist auch die zunehmende Akzeptanz des Lipofillings, d.h. der Brustvergrößerung durch Eigenfett. Dieses Verfahren der Eigenfettverpflanzung ist zwar prinzipiell nicht neu und wird seit über 10 Jahren eingesetzt zum Gesäß-Aufbau oder zur Faltenbehandlung im Gesicht. Bei der Brust jedoch waren seriöse Chirurgen bisher sehr zurückhaltend, da bis vor kurzem noch nicht ausreichend bekannt war, inwieweit durch ein solches Verfahren möglicherweise die Brustkrebsvorsorge beeinträchtigt werden kann oder ob das Eigenfett sogar ein Auslöser für Brustkrebs sein kann. Diesbezüglich scheint die Brustvergrößerung mit Eigenfett nach aktueller Datenlage jedoch unbedenklich zu sein, was sehr erfreulich ist, weil die Brustvergrößerung mit Eigenfett eine sehr schöne und vor allem natürliche Alternative zu Brustimplantaten bietet.“

 

 

Welche Operationen führen Sie am liebsten durch?

Eigentlich führen mein Team und ich alle von uns angebotenen Behandlungen nach wie vor sehr gern durch. Sogar Fettabsaugungen, obwohl diese körperlich sehr anstrengend sein können, denn die Patienten sind danach erfahrungsgemäß sehr zufrieden. Überhaupt freuen wir uns am meisten, wenn wir mit unserer Arbeit dazu beitragen können, dass sich unsere Patienten in ihrem Körper wohlfühlen.“

Weitere Informationen zur Praxisklinik für Plastische Chirurgie Dr. Eberlein in Bamberg finden Sie auf der homepage der Praxisklinik unter www.plastische-chirurgie-eberlein.de.

 

Praxisklinik für Plastische Chirurgie Dr. med. Aletta Eberlein,

Willy-Lessing-Straße 16, 96047 Bamberg

Tel. 0951-20877890

Sprechzeiten nach Vereinbarung

Parkplätze am Haus

Gesundheit/Medizin Pressemitteilungen

Cardiac Pacemaker Market trend, outlook 2026

Pacemaker is a device implanted on either (left or right) side of the chest and is connected with heart through pacing wires (also called as lead). It continuously monitors the heart rate and in case it detects slow heart rate, the device sends out electrical pulse to bring the heart rate to normal. Development of new products in pacemakers such as multi-chamber, two and three-chamber pacemakers, magnetic resonance imaging (MRI) compatible pacemakers, and leadless pacemaker has aided in greater adoption of this technology. This has led to growth of the market.
Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1765

Market Dynamics

New product launches by market players, owing to technological advancement in cardiac pacemakers are expected to drive growth of the market. Key manufacturers are engaged in launching more compact and efficient pacemaker device, which allows better control of abnormal heart rhythm along with additional specifications such as blood temperature monitor and breathing rate. For instance, in May 2016, Biotronik launched CardioMessenger Smart, portable monitoring device in the U.S. This system is about the size of a modern smartphone used to keep pacemaker, Implantable Cardioverter Defibrillator (ICD) and Insertable Cardiac Monitor (ICM) patients connected to their physician remotely. This CardioMessenger Smart helps to ensure patient compliance and the consistent transmission of data necessary for physicians to identify and prevent potential cardiac events. Moreover, high prevalence of cardiovascular disease is the major factor driving growth of global cardiac pacemaker market over the forecast period. As per statistics published by the World Health Organization (WHO), globally, an alarmingly high number of deaths resulted from cardiovascular disease in 2012, resulting in 31.0% or equating to 17.5 million lives. Among these, around 40.0% and 38.0% deaths were caused by coronary heart disease and stroke, respectively.

Request for Customizationhttps://www.coherentmarketinsights.com/insight/request-customization/1765

Key features of the study:

  • This report provides in-depth analysis of the cardiac pacemaker market, market size (US$ Mn) and compound annual growth rate (CAGR (%) for the forecast period: 2018 – 2026, considering 2017 as the base year

  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

  • It profiles leading players in the global cardiac pacemaker market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

  • Key players covered as a part of this study include Medtronic Plc, BIOTRONIK, Inc., Boston Scientific Corporation, Abbott Laboratories, Vitatron Holding B.V., Shree Pacetronix Ltd., MEDICO S.p.A., Lepu Medical Technology Co Ltd., LivaNova PLC, Qinming Medical, and Cordis Inc.

  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, technological up-gradation, market expansion, and marketing tactics

  • The global cardiac pacemaker market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for cardiac pacemaker market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Cardiac Pacemaker Market, By Product Type:

    • Single Chambered

    • Dual Chambered

    • Biventricular

    • Implantable Cardiac Pacemaker

    • External Cardiac Pacemaker

  • Global Cardiac Pacemaker Market, By End User:

    • Hospitals

    • Ambulatory Surgical Centers

  • Global Cardiac Pacemaker Market, By Region:

    • By Country:

      • U.S.

      • Canada

    • By Product Type:

      • Implantable Cardiac Pacemaker

      • Single Chambered

      • Dual Chambered

      • Biventricular

      • External Cardiac Pacemaker

    • By End User:

      • Hospitals

      • Ambulatory Surgical Centers

    • North America Cardiac Pacemaker Market

    • Europe Cardiac Pacemaker Market

      • By Country:

        • U.K.

        • Germany

        • Italy

        • Spain

        • France

        • Russia

        • Rest of Europe

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Gesundheit/Medizin Pressemitteilungen

Cellulite Treatment Market trend, outlook 2026

Cellulite is a condition in which a person’s skin of their thighs, buttocks, and hips appears dimpled. Common names for cellulite include cottage cheese skin, orange-peel skin, hail damage, and the mattress phenomenon. This condition is commonly observed in women than in men due to the fat deposition in a normal women represents between 18% and 20% of body weight, whereas in men it represents only 10% to 15%. According to 2015, article published by American Journal of Clinical Dermatology, around 80 and 90 percent of women are affected by cellulite at some point in their lives. Appearance of lumpiness beneath the skin due to fat deposits distorts and pushes the connective tissues, thus leads to the characteristic of cotton cheese appearance of the skin. Causes of cellulite are unidentified, however it seems to result from an interface between the fat layer and connective tissue in the dermatological layer, which is below the surface of the skin. Hormones such as noradrenaline, insulin, estrogen, prolactin, thyroid hormones play a significant role in cellulite development. Moreover, other factors such as genetics, age, diet, and lifestyle also affect cellulite development. Cellulite treatment market is significantly gaining traction due to increasing prevalence of obesity.

Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1773

Cellulite Treatment Market – Dynamics

One of the major drivers propelling growth of the cellulite treatment market is the growing obese population. For instance, according to 2014 National Institute of Diabetes and Digestives and Kidney Diseases report, 2 in 3 adults (70.2 percent) were diagnosed with obesity in the U.S. Moreover, advancements in technology such as Cellulaze™ the world’s first and only minimally invasive medical device designed to eliminate cellulite which uses SideLight 3D side-firing technology to target the causes of cellulite beneath the skin, are boosting the growth of the cellulite treatment market size. For instance, according to 2017, American Society of Plastic Surgeons report, around 1.8 million cosmetic surgical procedures were performed in 2017. Growing inclination towards achieving a slim body, lighter complexion, and better skin is also boosting demand for cosmetic treatment for cellulite. Furthermore, various technological advancement such as user-friendly pen shaped portable laser medical devices, is expected to boost growth of the market.

However, a major factor restraining growth of the cellulite treatment market is a popular alternative herbal massage treatment, which includes acupuncture, gua sha, and cupping techniques. Furthermore, high cost of cosmetic surgeries are expected to hamper the market growth.

Request for TOChttps://www.coherentmarketinsights.com/ongoing-insight/toc/1773

Cellulite Treatment Market – Regional Insights

On the basis of the region, the global cellulite treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global market, owing to adoption of the innovative medical products and treatments, For instance, in 2015, The Food and Drug Administration (FDA) approved Cellina, a non-invaise cellulite treatment. Moreover U.S is observing fast increase in aging population, is expected to create robust demand for aesthetic repair market services in the country. For instance, According to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, it was estimated that over 11 million aesthetic procedures were performed by board?certified specialists, of which 16.5% were surgical procedures and 83.5% were non?surgical procedures.

Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to growing obese population in this region and increasing disposable income among the populace in the region.  According to 2017 Asian Development Bank Institute report Asia and the Pacific region is home to the largest absolute number of overweight and obese people, equivalent to about 1 billion.

Cellulite Treatment Market – Competitive Insights

Key players operating in the global cellulite treatment market include Tanceuticals, LLC., Nubway, Merz Pharma GmbH & Co. KGaA, Zimmer Aesthetics, Cymedics, Cynosure, Inc., Inceler Medikal Co. Ltd., and Syneron Medical Inc. Market players are focused towards collaborations and providing technologically advanced products to sustain their presence in the market.

Cellulite Treatment Market – Taxonomy

On the basis of treatment procedure, the global cellulite treatment market is segmented into:

  • Non-invasive

  • Minimally-invasive

  • Topical Treatment

On the basis of cellulite, the global cellulite treatment market is segmented into:

  • Soft Cellulite

  • Hard Cellulite

  • Edematous Cellulite

On the basis of end user, the global cellulite treatment market is segmented into:

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialized Dermatology Clinics

On the basis of geography, the global cellulite treatment market is segmented into:

  • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Gesundheit/Medizin Pressemitteilungen

Erythromycin Market trend, outlook 2026

Erythromycin is an antibiotic, which is used to treat certain kind of bacterial infections. Erythromycin topical preparations are largely used on the skin to help control acne. The antibiotic is also used in combination with other medicines and are applied topically or taken orally for treating the infections. The common side effects of erythromycin include nausea, loss of appetite, diarrhea, and abdominal pain. Erythromycin prevents bacterial cells from growing and multiplying by interfering with their ability to make proteins, while not affecting human cells. It is widely used to treat chest infections such as pneumonia, skin problems such as acne and rosacea, dental abscesses, and sexually transmitted infections.

Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1780

Erythromycin Market Dynamics

Pharmaceutical manufacturers are focused on increasing access to affordable medications to provide novel options for patients and pharmacists, thereby addressing the limited availability of erythromycin tablets, which in turn is expected to augment market growth. For instance, in March, 2018, Amneal Pharmaceuticals received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The erythromycin product is a therapeutic equivalent for the reference listed drug (RLD) erythromycin tablets from Arbor Pharmaceuticals and is the only other immediate release oral tablet available. Moreover, in September 2016, ANI Pharmaceuticals, Inc. launched Erythromycin Ethylsuccinate for oral suspension 200mg/5mL indicated as a treatment for various infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires disease, pertussis, and others.

Moreover, rising prevalence of various infectious diseases including respiratory tract infections is a major factor expected to augment growth of the erythromycin market size in the near future. According to the study by Bill & Melinda Gates Foundation, 2015, an estimated 2.74 million deaths were recorded due to lower respiratory tract infections (LRIs) and 103.0 million disability-adjusted life-years (DALYs) globally. This is expected to increase adoption of antibiotics.

However, signs of allergic reaction to erythromycin such as swelling of the mouth, face, lips, tongue, or throat and increasing availability of alternatives such as azithromycin are factors hindering growth of the global erythromycin market. Furthermore, pregnant women are warned from using these antibiotic pills as the researchers from Great Ormond Street Hospital and University College London, 2015, stated that erythromycin pills are linked with higher risks of epilepsy and cerebral palsy in the newborn babies.

Request for TOChttps://www.coherentmarketinsights.com/ongoing-insight/toc/1780

Key features of the study:

  • This report provides in-depth analysis of respiratory devices market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

  • It profiles leading players in the global respiratory devices market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

  • Key companies covered as a part of this study include Koninklijke Philips N.V., 3M, AstraZeneca Plc., GE Healthcare, GlaxoSmithKline Plc., Medtronic, Becton, Dickinson and Company, Invacare Corporation, ResMed, Inc., and CareFusion CorporationErythromycin Market – Regional Dynamics

Regional segmentation of the global erythromycin market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America erythromycin market is expected to hold a dominant position over the forecast period, owing to rising number of regulatory approvals of drugs by regulatory agencies to address the unmet medical needs of the patients and increasing prevalence of skin and soft tissue infections. For instance, in November, 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Erythromycin and Benzoyl Peroxide Topical Gel USP, 3-5% an FDA-approved generic version of Valeant International’s Benzamycin Gel, 3-5%. According to the Division of Infectious Diseases, Los Angeles BioMedical Research Center, 2015, skin and soft tissue infections (SSTIs) are a common reason to seek medical care in the U.S. as they can lead to complications with significant morbidity, including hospitalization, surgical procedures, or death.

Erythromycin Market- Competitive Analysis

Manufactures are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals, thereby augmenting the market growth. For instance, in July 2017, Teligent, Inc., a generic pharmaceutical company, received approval for its abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Erythromycin Topical Gel USP, 2%. Furthermore, in 2010, Akorn, Inc. received the U.S. Food and Drug Administration (FDA) approval for the company’s Abbreviated New Drug Application (ANDA) supplement for Erythromycin Ophthalmic Ointment USP 3.5 g.

Key players operating in the global erythromycin market include Ani Pharmaceuticals, Akorn, Inc., Aceto Corporation, Genesis Pharmaceuticals, Teligent, Inc., Abbvie, Inc., Abbott Laboratories, Pfizer, Inc., Sanofi-Aventis, and Allergan, Plc.

Erythromycin Market Taxonomy

On the basis of formulation, the global erythromycin market is segmented into:

  • Gel

  • Tablet

  • Topical Solution

  • Ointment

  • Others

On the basis of therapeutic indications, the global erythromycin market is segmented into:

  • Respiratory Tract Infections

  • Eye Infections

  • Ear Infections

  • Skin and Soft Tissue Infections

  • Gastro-intestinal Infections

  • Others

On the basis of distribution channel, the global erythromycin market is segmented into:

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

On the basis of region, the global erythromycin market is segmented into:

  • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East

  • Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Gesundheit/Medizin Pressemitteilungen

Röntgenbildentsorgung nur mit DSGVO-konformen AV-Verträgen

Warum Praxen und Kliniken vorgelegte Verträge zur Auftragsverarbeitung genau prüfen sollten

Bremen, 22. Juni 2018Artikel 28 der seit 25. Mai 2018 geltenden Datenschutzgrundverordnung (DSGVO) schreibt Verträge zur Auftragsverarbeitung – sogenannte AV-Verträge bzw. Datenschutzverträge zwischen medizinischen Einrichtungen und externen Dienstleistern vor, die deren personenbezogene Daten verarbeiten. Entsorger von Röntgenfilmen und dazugehörigen Patientenakten gehören zu den Dienstleistern, die AV-Verträge zur Konkretisierung bestehender Dienstleistungsverträge vorlegen müssen. Abfall- und Datenschutzbeauftragte, Justitiare oder auch mit Entsorgungsfragen betraute Mitarbeiter in ärztlichen Praxen sind in der Pflicht, diese zu prüfen, auszufüllen und zurückzusenden. Dabei müssen sie die Vereinbarungen zuallererst auf ihre DSGVO-Konformität überprüfen. Verträge, die den Entsorgungsprozess nicht umfassend abbilden, Subunternehmer nicht ausweisen und in den Anlagen keine Zertifikate enthalten, sind kritisch zu betrachten und ggf. an einen Juristen zur weiteren Prüfung zu übergeben.

„Wir arbeiten ausschließlich mit rechtlich einwandfreien und geprüften AV-Verträgen nach Artikel 28 DSGVO“, bekräftigt Monica Calvo Moreno, Datenschutzkoordinatorin und Vertriebsleiterin von Schmidtentsorgung. Die Verträge zur Entsorgung von Röntgenfilmen behandeln entsprechend den Gegenstand und die Dauer des Auftrags, die Konkretisierung des Auftragsinhalts, technisch-organisatorische Maßnahmen, die Berichtigung, Einschränkung und Löschung von Daten, die Pflichten des Auftragnehmers, Unterauftragsverhältnisse, Kontrollrechte des Auftraggebers, Mitwirkungspflichten des Auftragnehmers, die Weisungsbefugnis des Auftraggebers, die Löschung und Rückgabe von personenbezogenen Daten sowie die Geheimhaltungspflichten. „Unser Zertifikat über die bei der Röntgenfilmentsorgung weiterhin maßgebliche DIN SPEC 66399-3 ist ebenso Bestandteil der Verträge. Damit weisen wir unsere fachliche Kompetenz gemäß Artikel 28 DSGVO nach“, ergänzt Moreno.

„Wichtig ist, dass sich Kliniken und Praxen die Zeit nehmen, empfangene Verträge genauestens zu lesen, Fragen zu den Datenarten und deren Schutzbedarf zu beantworten, eventuelle Subunternehmer hinsichtlich ihrer Fachkunde zu begutachten und beigefügte Zertifikate durch einen Anruf beim jeweiligen Zertifizierer auf ihre Echtheit und Gültigkeit zu prüfen“, erklärt Moreno. Entsorger, die über keine eigene Entsorgungsanlage oder keine internen Sortierkapazitäten verfügen, müssen diese Lücken im Entsorgungsprozess durch Subunternehmen füllen, die im AV-Vertrag namentlich, mit Adresse und Zertifikat auszuweisen sind.

Schmidtentsorgung ist im Bereich Datenschutz seit vielen Jahren zertifiziert. Demgemäß entspricht die Entsorgung von Röntgenfilmen vollumfänglich den neuen Anforderungen der Datenschutzgrundverordnung. Schmidt + Kampshoff kann dank eigener Anlage in Rhede, eigener Sortierung, auf den Datenschutz verpflichteter Mitarbeiter, abschließbarer Datensicherheitsbehälter und GPS-überwachter Fahrzeugflotte einen rundum geschlossenen, sicheren Entsorgungsprozess aus einer Hand anbieten.

Weiterführende Informationen zur datenschutzkonformen Aufbewahrung und Entsorgung von Röntgenfilmen und dazugehöriger Patientenakten unter www.schmidtentsorgung.de.

Kontakt: Monica Calvo Moreno, Schmidt + Kampshoff GmbH, Georg-Henschel-Str. 1, 28197 Bremen, Telefon: +49 421 835 444 0, Telefax: +49 421 835 444 11, E-Mail: monica.calvo-moreno@schmidtentsorgung.de

Pressekontakt: Katrin Sturm, Agenda 17. Agentur für Public Relations, Dittrichring 17, 04109 Leipzig, Telefon: +49 341 980 90 90, Telefax: +49 341 980 89 17, E-Mail: info@agenda17.de

Gesundheit/Medizin

Intelligent Stethoscope Market Development Report: Current Growth, New Technology, Sharp Details and Future Prospects by 2025

Worldwide Market Reports added Latest Research Report titled “Intelligent Stethoscope Market Research Report 2018” to its Large Report database. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing capital structure of the Intelligent Stethoscope Industry.

In this report, the global Intelligent Stethoscope market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/intelligent-stethoscope-market-72

Geographically, this report is segmented into several key Regions, with production, consumption, revenue million USD, market share and growth rate of Intelligent Stethoscope in these regions, from 2013 to 2025 forecast, covering

  • North America
  • Europe
  • China
  • Japan
  • Southeast Asia
  • India

Global Intelligent Stethoscope market competition by top manufacturers, with production, price, revenue value and market share for each manufacturer; the top players including

  • A&D Medical
  • Eko Devices
  • American Diagnostic Corporation
  • Rudolf Riester GmbH & Co. KG
  • Escalon Medical Corporation
  • GF Health Products Inc.
  • MediStim ASA
  • Medline Industries Inc.
  • Tytan Medical Corp
  • Thinklabs Medical LLC
  • eKuore
  • Soumac

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

  • Wired Stethoscope
  • Wireless Stethoscope

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption sales, market share and growth rate for each application, including

  • Hospital
  • Clinic
  • Household

Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/intelligent-stethoscope-market-72

Table of content

Global Intelligent Stethoscope Market Research Report 2018
1 Intelligent Stethoscope Market Overview
1.1 Product Overview and Scope of Intelligent Stethoscope
1.2 Intelligent Stethoscope Segment by Type Product Category
1.2.1 Global Intelligent Stethoscope Production and CAGR % Comparison by Type Product Category20132025
1.2.2 Global Intelligent Stethoscope Production Market Share by Type Product Category in 2017
1.2.3 Wired Stethoscope
1.2.4 Wireless Stethoscope
1.3 Global Intelligent Stethoscope Segment by Application
1.3.1 Intelligent Stethoscope Consumption Sales Comparison by Application 20132025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household

2 Global Intelligent Stethoscope Market Competition by Manufacturers
2.1 Global Intelligent Stethoscope Capacity, Production and Share by Manufacturers 20132018
2.1.1 Global Intelligent Stethoscope Capacity and Share by Manufacturers 20132018
2.1.2 Global Intelligent Stethoscope Production and Share by Manufacturers 20132018
2.2 Global Intelligent Stethoscope Revenue and Share by Manufacturers 20132018
2.3 Global Intelligent Stethoscope Average Price by Manufacturers 20132018

3 Global Intelligent Stethoscope Capacity, Production, Revenue Value by Region 20132018
3.1 Global Intelligent Stethoscope Capacity and Market Share by Region 20132018
3.2 Global Intelligent Stethoscope Production and Market Share by Region 20132018
3.3 Global Intelligent Stethoscope Revenue Value and Market Share by Region 20132018

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/intelligent-stethoscope-market-72

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports

Gesundheit/Medizin Pressemitteilungen

Blood Processing Devices and Consumables Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled “Blood Processing Devices and Consumables Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis” to its Large Report database.

The Global Blood Processing Devices and Consumables Market was valued at US$ 27.8 billion in 2015, according to a new report by published by Coherent Market Insights. Increasing geriatric population and rising emphasis of leading companies’ on long-term partnerships with end users is expected to boost demand for blood processing devices and consumables over the forecast period (2016-2024).
Blood processing devices and consumables market size has grown manifold over the last decade. Much of its growth was attributed to government initiatives in setting up of blood screening center, especially in developing countries. The trend is especially prevalent in China, India, and Russia, with rampant increase in number of blood centers in these countries in the recent past. As a result of this, lucrative growth opportunities have emerged for industry players to expand their business reach across developing regions and enhance ROI over the forecast period.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187542

There has been an increase in incidence rate of infectious diseases and chronic disorders such as cancer, especially among the geriatric population. According to the World Health Organization (WHO), in 2015, over 150 million people suffered from chronic hepatitis C virus, of which 700 thousand die each year owing to lack of suitable healthcare infrastructure and diagnosis centers. Technological advancements in the healthcare industry is expected to bridge the gap between patient’s expectation and healthcare delivery system. While the market for blood processing devices and consumables is highly saturated in developed regions, the developing regions, especially Asia Pacific is largely untapped and offers lucrative growth opportunities for market players.

Request for Discount @ https://www.worldwidemarketreports.com/discount/187542

Key takeaways of the market
• Government has a critical role in creating national platforms for blood screening and blood bank centers. Increasing geriatric population along with rise in incidence rate of blood-related disorders is expected to create lucrative market opportunities for industry players
• Cell processors device segment is expected to dominate the global blood processing devices market (in terms of revenue) throughout the forecast period. While, blood bags device segment is expected to lead the consumables market throughout the forecast period.
• Asia Pacific dominated the global blood processing devices and consumables market, with a revenue share of around 17% of the total market in 2015. Growth of the regional market is mainly propelled by increasing demand from China, which accounted for 39% revenue share of the market in the region. The blood processing devices and consumables market in India is expected to expand at the highest CAGR in Asia Pacific during the forecast period.
• North America and Europe are highly matured market. Leading players such as Abbott Laboratories, Roche Holdings AG, and Terumo Corporation are emphasizing on establishing a direct distribution channel to retain their dominance in these regional markets. Setting up of cord blood bank center in these region is expected to create substantial market opportunity for industry players. Over 23 million blood components are transfused each year in North America.
• There are over 13 thousand blood bank centers worldwide. The number is especially high in low to middle income countries, particularly India, Indonesia and Vietnam. Establishment of blood bank centers is expected to boost overall demand for blood bank refrigerators worldwide. The blood bank market is highly consolidated, with leading players accounting for around 80% of the global market. New entrants are expected to provide bank refrigerators during the forecast period.
• While the overall blood processing device segment is consolidated, it is highly fragmented in consumables segment with large presence of regional players, especially in China and India.

Browse more detail information about Blood Processing Devices and Consumables Market Report at :https://www.worldwidemarketreports.com/market-insights/blood-processing-devices-and-consumables-market-global-industry-insights-trends-outlook-and-opportunity-analysis

** If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703
Email : sales@worldwidemarketreports.com
Visit our website for more details : https://www.worldwidemarketreports.com
Visit our new website for latest News : https://www.industrychronicle.com

Gesundheit/Medizin Pressemitteilungen

Companion Diagnostics Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled “Companion Diagnostics Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis” to its Large Report database.

The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test products.
The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks. AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion diagnostics in treating chronic diseases.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187552

Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.

Request for Discount @ https://www.worldwidemarketreports.com/discount/187552

Key takeaways of the global companion diagnostics market:
• The global companion diagnostics market is expected to expand at a CAGR of 12% during the forecast period (2016-2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally
• The breast cancer application in the global companion diagnostics market was estimated to be the largest in 2015 and is expected to dominate the companion diagnostics market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer.
• In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies.
• The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in companion diagnostics market has increased from 13 in 2007 to 66 in 2013.
• Some of the major players in the global companion diagnostics market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare.

Browse more detail information about Companion Diagnostics Market Report at:https://www.worldwidemarketreports.com/market-insights/companion-diagnostics-market-global-industry-insights-trends-outlook-and-opportunity-analysis

** If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703
Email : sales@worldwidemarketreports.com
Visit our website for more details : https://www.worldwidemarketreports.com
Visit our new website for latest News : https://www.industrychronicle.com

Gesundheit/Medizin Pressemitteilungen

Elderly and Disabled Assistive Devices Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis

Worldwide Market Reports added Latest Research Report titled “Elderly and Disabled Assistive Devices Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis” to its Large Report database.

The Global Elderly and Disabled Assistive Devices Market was valued at US$ 14,109.1 million in 2015 and is projected to expand at a CAGR of 7.4% during the forecast period (2016-2024), according to a new report published by Coherent Market Insights. Rapidly aging population in Asia and Latin America is a major factor propelling demand for elderly and disabled assist devices.
Asia and Latin America are expected to witness rapid growth in population aged 65 years and above through 2030. The share of elderly population in Asia is expected to increase form 7.9% in 2015 to 12.1% in 2030, as per the report ‘An Aging World: 2015′ by the U.S. Census Bureau. Also, increasing prevalence of chronic and acute diseases adds to the growing demand for technologically-advanced assistive devices for elderly and disabled population. Assistive devices such as wheelchairs, mobility scooters, walkers and rollators, and hearing and vision aids reduces dependence on others to carry out daily activities and improves quality of life of elderly and disabled patients.

Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/187541

The World Health Organization (WHO) has prepared a comprehensive global disability action plan for 2014 – 2021. As per this plan, WHO intends to improve access to health services and programs, extend rehabilitation, assistive technology, assistance and support services, and support research on disability and related services. Assistive device manufacturers in the elderly and disabled assist devices market, especially in emerging economies are expected to benefit considerably through this plan.
Manufacturers in the elderly and disabled assist devices market are reaching out directly to consumers to increase their sales. Sonova Holding AG follows vertically-integrated business, wherein it also markets products through its retail stores, thus reaching out to customers and offering them customized solutions. The company acquired AudioNova in September 2016—a Netherlands-based hearing aid manufacturer—with an aim to double its presence in Europe in terms of retail stores.
Melvin ApS launched a robot called Melvin, which aids elderly and disabled people in the toilet. The robot was launched at the RoboBusiness Europe 2016 exhibition. Similarly, Vital Connect, Inc.is developing wearable health sensors that can detect body temperature, heart rate, detect falls and other such incidents in elderly and disabled patients. Such technological developments to increase individual independence and convenience is projected to lead to manifold growth of elderly and disabled assistive devices market in the near future.

Request for Discount @ https://www.worldwidemarketreports.com/discount/187541

Key takeaways of the market:
• The global elderly and disabled assist devices market is expected to expand at a CAGR of 7.4% during the forecast period. Increasing demand for elderly and disabled assist devices is mainly attributed to the factors such as convenience provided by automotive assistive devices to the growing elderly and disabled population
• Demand for vision and reading aids is analyzed to increase rapidly during the forecast period, owing to increasing incidence of vision impairment among the geriatric populace
• Hearing aids segment dominates the global elderly and disabled assist devices market (in terms of revenue) and is expected to reach US$ 7,083.5 million by 2017 end. Increasing market penetration, growing average discretionary income, and improved access to hearing aids is driving revenue growth of this segment. Furthermore, baby boomers population is expected to drive growth for hearing aids over the following decade, according to William Demant Holding Group.
• North America dominated the global elderly and disabled assist devices market in 2015. However, the market for elderly and disabled assistive devices in Asia Pacific is projected to expand significantly at a CAGR of 8.7% during the forecast period (2016-2024)
• Intense competition is witnessed among the leading players including Sunrise Medical LLC, GN ReSound Group, Sonova Holding AG, Starkey Hearing Technologies, and William Demant Holding A/S.

Browse more detail information about Elderly and Disabled Assistive Devices Market Report at: https://www.worldwidemarketreports.com/market-insights/elderly-and-disabled-assistive-devices-market-global-industry-insights-trends-outlook-and-opportunity-analysis

** If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703
Email : sales@worldwidemarketreports.com
Visit our website for more details : https://www.worldwidemarketreports.com
Visit our new website for latest News : https://www.industrychronicle.com